Iron isomaltoside/ferric derisomaltose — Competitive Intelligence Brief

Iron isomaltoside/ferric derisomaltose (Iron isomaltoside/ferric derisomaltose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron replacement therapy. Area: Hematology.

phase 3 Iron replacement therapy Iron metabolism pathway; ferric iron (Fe3+) Hematology Small molecule

Target snapshot

Iron isomaltoside/ferric derisomaltose (Iron isomaltoside/ferric derisomaltose) — Pharmacosmos A/S. Iron isomaltoside delivers ferric iron complexed with isomaltoside, a carbohydrate polymer, to replenish iron stores and treat iron deficiency anemia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Iron isomaltoside/ferric derisomaltose TARGET	Iron isomaltoside/ferric derisomaltose	Pharmacosmos A/S	phase 3	Iron replacement therapy	Iron metabolism pathway; ferric iron (Fe3+)
Low Molecular Weight Iron Dextran	Low Molecular Weight Iron Dextran	University of Washington	marketed	Iron replacement therapy
Parentral Iron	Parentral Iron	Services Institute of Medical Sciences, Pakistan	marketed	Iron replacement therapy
Supplementation of iron sucrose	Supplementation of iron sucrose	Medical University of Vienna	marketed	Iron replacement therapy
Iron-Dextran Complex Injection [InFed]	Iron-Dextran Complex Injection [InFed]	Oregon Health and Science University	marketed	Iron replacement therapy
IV iron infusion	IV iron infusion	NICHD Global Network for Women's and Children's Health	marketed	Iron replacement therapy
IV iron - Sodium Ferric Gluconate Complex	IV iron - Sodium Ferric Gluconate Complex	Rambam Health Care Campus	marketed	Iron replacement therapy	Iron (Fe3+) delivery to erythropoietic tissues

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron replacement therapy class)

1. AMAG Pharmaceuticals, Inc. · 1 drug in this class
2. Medical University of Vienna · 1 drug in this class
3. NICHD Global Network for Women's and Children's Health · 1 drug in this class
4. Nicoletta C Machin · 1 drug in this class
5. Oregon Health and Science University · 1 drug in this class
6. Pharmacosmos A/S · 1 drug in this class
7. Rambam Health Care Campus · 1 drug in this class
8. Services Institute of Medical Sciences, Pakistan · 1 drug in this class
9. Sumitomo Pharma America, Inc. · 1 drug in this class
10. University of Washington · 1 drug in this class